Identification and characterization of human KALRN mRNA and Kalirin protein isoforms.
Mould AW. et al, (2024), Cereb Cortex, 34
Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements.
Griffen EJ. et al, (2024), Wellcome Open Res, 9
An Update on SARS-CoV-2 Clinical Trial Results-What We Can Learn for the Next Pandemic.
Arman BY. et al, (2023), Int J Mol Sci, 25
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.
Boby ML. et al, (2023), Science, 382
Accelerating antiviral drug discovery: lessons from COVID-19.
von Delft A. et al, (2023), Nat Rev Drug Discov, 22, 585 - 603
Turning high-throughput structural biology into predictive inhibitor design.
Saar KL. et al, (2023), Proc Natl Acad Sci U S A, 120
SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids.
Jansen J. et al, (2022), Cell Stem Cell, 29, 217 - 231.e8
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia.
Mould AW. et al, (2022), CNS Drugs, 36, 1 - 16
A white-knuckle ride of open COVID drug discovery.
von Delft F. et al, (2021), Nature, 594, 330 - 332
Incoming HIV virion-derived Gag Spacer Peptide 2 (p1) is a target of effective CD8+ T cell antiviral responses.
Yang H. et al, (2021), Cell Rep, 35
Open Science Discovery of Potent Non-Covalent SARS-CoV-2 Main Protease Inhibitors
Boby ML. et al, (2020)
Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes.
Donnison T. et al, (2020), Vaccine, 38, 5036 - 5048
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Esposito I. et al, (2020), Sci Transl Med, 12
MHC-II invariant chain adjuvanted chimpanzee adenoviral and MVA hepatitis C vaccines elicit unprecedented levels of anti-viral T-cell immune responses in humans
Esposito I. et al, (2019), JOURNAL OF HEPATOLOGY, 70, E3 - E4
The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes.
von Delft A. et al, (2018), Vaccine, 36, 313 - 321
A pan-genotype HCV T cell vaccine, in a simian adenovirus vector, to target T cell epitopes conserved across multiple HCV genotypes
Donnison T. et al, (2018), JOURNAL OF HEPATOLOGY, 68, S800 - S801
Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus.
Ansari MA. et al, (2017), Nat Genet, 49, 666 - 673